Pamedic Moment | Exploring Actinium in Radiopharmaceuticals[225Ac]

Radiopharmaceuticals, the new star in medical field nowadays, are gradually ejectsing their unlimited potential in cancer treatment and diagnosis. Among them, actinium [225Ac], a cutting-edge nuclide, is the new hope for cancer treatment following lutetium [177Lu], and their related labelled medicines are undergoing rapid clinical transformation, which is the focus of the medical field. As an isotope research company, Pamedic Holdings is deeply committed to the research and application of actinium [225Ac] to provide patients with more accurate and effective treatment options.

What is a radiopharmaceutical

Radiopharmaceuticals, also known as nuclear medicine, are used in clinical diagnosis or treatment as radionuclide agents or their labelled compounds. Nuclear medicine is curently awidely used in oncology, myocardial imaging, early detection of neurodegenerative diseases, and diagnosis of inflammatory tissue imaging. Radiopharmaceuticals can make use of the biological characteristics of their labelled carriers to reflect the genes, molecules, metabolism and functional status of the disease, and can provide earlier and more specific insight into the molecular level of the disease, and can also make use of the radionuclide's ray energy to kill and maim tumours accurately, which has become a powerful means for early diagnosis of the disease and precise treatment. Radiopharmaceuticals are generally divided into diagnostic radiopharmaceuticals (including in vitro radioimmuno-diagnostic medicines) and therapeutic radiopharmaceuticals. By the type of nuclide, they are divided into y-nuclide, β-nuclide, and a-nuclide labelled medicines.

Types of radionuclides

Gamma nuclides: used mainly for diagnostic purposes and can provide high resolution images.

Beta nuclides: suitable for therapeutic use, capable of killing cancer cells.

Alpha nuclides: have a higher particle mass and shorter range, achieving a high degree of cytotoxicity in the target area with less damage to surrounding tissues.

The Uniqueness and Potential of Actinium [225Ac]

Actinium [225Ac] not only has a half-life of 10 days and highly efficient radioactivity, but more importantly, it is able to achieve a high degree of radiolytic effect in target cells while reducing damage to surrounding healthy tissues, which makes actinium [225Ac] an excellent performer in cancer therapy, with good therapeutic potential, especially in tiny tumour foci widely distributed throughout the body. Therefore, Actinium [225Ac] can be used in difficult-to-treat cancers such as pancreatic cancer, prostate cancer, neuroendocrine tumors, breast cancer and leukaemia.

The Research and Development of Actinium [225Ac]

Several biotechnology companies and research institutes around the world have made significant progress in the research and clinical application of actinium [225Ac]. Several actinium [225Ac]-labelled nuclear medicines have entered into different stages of clinical trials, showing great therapeutic potential and market prospects, especially in China and overseas.

Radiopharmaceuticals, particularly actinium [225Ac], represent an important direction of innovation in medicine. With technological advances and growing market demand, this field will provide more precise and effective treatments for cancer patients. In the future, we can look forward to more innovative research and applications of actinium [225Ac] and other radiopharmaceuticals, opening up a new chapter for human health.

Radiopharmaceuticals Development prospects

01 Growing market demand: As the global population ages and chronic diseases increase, the need for more accurate and earlier diagnosis and treatment is growing as the result. Eyeballs have been attracted to radiopharmaceuticals are for their wide range of applications in the diagnosis and treatment of cancer, heart disease and other neurological disorders.

02 Technological progress and innovation: As medical technology advances, the ability of radiopharmaceuticals to diagnose and treat diseases at the molecular level is growing. New radiolabelling techniques and therapies leads to greater potential for innovation in this area. A plenty of biotechnology and pharmaceutical companies are entering this field to conduct innovative research after they acquired further knowledge of certain intractable diseases increases (e.g. certain cancers and neurodegenerative diseases).

03 Political and regulatory support: Many governments around the world have recognised the potential of radiopharmaceuticals and urge to improve the quality and efficiency of healthcare services with providing appropriate policy and regulatory support, which has played a positive role in promoting clinical research on radiopharmaceuticals for in vivo treatment.

04 Global development trend: With the deepening of globalisation, the radiopharmaceutical market has become more open and competitive, attracting investors and enterprises from different countries and regions.

About PanMediso

Pamedic Holdings is committed to making breakthroughs in the field of nuclear medicine, and we always keep a close eye to the industry trends and strengthen our competitiveness to meet the diverse needs of patients.

Pamedic Holdings, bearing the dream to bring China's nuclear drug industry to the international stage and provide patients with more advanced and personalised treatment options, will continue to ramp up the investment in R&D, intensify technological innovation, and expand our product lines by introducing cutting-edge technologies as well as combining them with our own R&D. 

Pamedic Holdings will move the nuclear medicine industry forward and make greater contributions to human health while building global partnerships.